B Cell Responses in COVID-19

N/ACompletedNCT06891170

Fondazione IRCCS Policlinico San Matteo di Pavia4 enrolled

Overview

In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID 19

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>18 at time of signing informed consent form * Signed informed consent form Exclusion Criteria: * Ongoing drug abuse * Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Ischemic heart disease * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form

Locations (1)

Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, Pavia, Italy

Outcomes

Primary Outcomes

Optimization of the method to obtain human mAbs neutralizing COVID-19.

Time frame: From enrollment to 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.